Selected article for: "antibody response and cellular immune response"
Author: Wang, Shixia; Heilman, Destin; Liu, Fangjun; Giehl, Theodore; Joshi, Swati; Huang, Xiaoyun; Chou, Te-hui; Goguen, Jon; Lu, Shan
Title: A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague
  • Cord-id: p6w6awsu
  • Document date: 2004_9_3
    • ID: p6w6awsu
    Snippet: There is an urgent need to develop effective vaccines against pneumonic plague, a highly lethal and contagious disease caused by the Gram-negative bacterium Yersinia pestis. Here we demonstrate that a novel DNA vaccine expressing a modified V antigen (LcrV) of Y. pestis, with a human tissue plasminogen activator (tPA) signal sequence, elicited strong V-specific antibody responses in BALB/c mice. This tPA-V DNA vaccine protected mice from intranasal challenge with lethal doses of Y. pestis. In co
    Document: There is an urgent need to develop effective vaccines against pneumonic plague, a highly lethal and contagious disease caused by the Gram-negative bacterium Yersinia pestis. Here we demonstrate that a novel DNA vaccine expressing a modified V antigen (LcrV) of Y. pestis, with a human tissue plasminogen activator (tPA) signal sequence, elicited strong V-specific antibody responses in BALB/c mice. This tPA-V DNA vaccine protected mice from intranasal challenge with lethal doses of Y. pestis. In comparison, a DNA vaccine expressing the wild type V antigen was much less effective. Only tPA-V formed oligomers spontaneously, and elicited a higher IgG2a anti-V antibody response in immunized mice, suggesting increased T(H)1 type cellular immune response. Our data indicate that antigen engineering is effective in inducing high quality protective immune responses against conformationally sensitive antigens. These results support that optimized DNA vaccines have the potential to protect against bacterial pathogens than is generally recognized.

    Search related documents:
    Co phrase search for related documents
    • active remain and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7
    • active search and acute pneumonia: 1
    • active search and acute respiratory syndrome: 1, 2, 3
    • active site and acute pneumonia: 1, 2, 3
    • active site and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active site and local infection: 1, 2
    • active site and low protection: 1
    • acute pneumonia and local infection: 1
    • acute pneumonia and lymph node: 1, 2
    • acute respiratory syndrome and local infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and long delay: 1
    • acute respiratory syndrome and low level expression: 1, 2, 3, 4, 5, 6
    • acute respiratory syndrome and low protection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute respiratory syndrome and lymph node: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • local infection and lymph node: 1
    • low level expression and lymph node: 1, 2